BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 7515446)

  • 1. Genetic susceptibility of benign prostatic hyperplasia.
    Sanda MG; Beaty TH; Stutzman RE; Childs B; Walsh PC
    J Urol; 1994 Jul; 152(1):115-9. PubMed ID: 7515446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial aggregation of bothersome benign prostatic hyperplasia symptoms.
    Pearson JD; Lei HH; Beaty TH; Wiley KE; Isaacs SD; Isaacs WB; Stoner E; Walsh PC
    Urology; 2003 Apr; 61(4):781-5. PubMed ID: 12670565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia cases - a medium term, prospective, randomized comparison.
    Geavlete B; Stanescu F; Iacoboaie C; Geavlete P
    BJU Int; 2013 May; 111(5):793-803. PubMed ID: 23469933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Epidemiology and natural course of benign prostatic hyperplasia].
    Blom JH; Schröder FH
    Urologe A; 1992 May; 31(3):129-34. PubMed ID: 1377429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The natural history of benign prostatic hyperplasia.
    Fitzpatrick JM
    BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpreting results of prostate-specific antigen testing for early detection of prostate cancer.
    Meigs JB; Barry MJ; Oesterling JE; Jacobsen SJ
    J Gen Intern Med; 1996 Sep; 11(9):505-12. PubMed ID: 8905498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
    Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
    BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis.
    Luo J; Dunn T; Ewing C; Sauvageot J; Chen Y; Trent J; Isaacs W
    Prostate; 2002 May; 51(3):189-200. PubMed ID: 11967953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network.
    Hellwege JN; Stallings S; Torstenson ES; Carroll R; Borthwick KM; Brilliant MH; Crosslin D; Gordon A; Hripcsak G; Jarvik GP; Linneman JG; Devi P; Peissig PL; Sleiman PAM; Hakonarson H; Ritchie MD; Verma SS; Shang N; Denny JC; Roden DM; Velez Edwards DR; Edwards TL
    Sci Rep; 2019 Apr; 9(1):6077. PubMed ID: 30988330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into the epidemiology and natural history of benign prostatic hyperplasia.
    Boyle P
    Prog Clin Biol Res; 1994; 386():3-18. PubMed ID: 7528398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the α-adrenergic receptor antagonist.
    Qian X; Xu D; Liu H; Lin X; Yu Y; Kang J; Sheng X; Xu J; Zheng S; Xu D; Qi J
    Aging Male; 2017 Dec; 20(4):250-256. PubMed ID: 28787260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are clinical characteristics of familial benign prostatic hyperplasia different than in sporadic cases?
    Tan MO; Diker Y; Uygur MC; Karabiyik I; Erol D
    Urol Int; 2002; 68(3):178-82. PubMed ID: 11919464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for autosomal dominant inheritance of prostate cancer.
    Schaid DJ; McDonnell SK; Blute ML; Thibodeau SN
    Am J Hum Genet; 1998 Jun; 62(6):1425-38. PubMed ID: 9585590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10.
    Li Z; Habuchi T; Tsuchiya N; Mitsumori K; Wang L; Ohyama C; Sato K; Kamoto T; Ogawa O; Kato T
    Carcinogenesis; 2004 Feb; 25(2):237-40. PubMed ID: 14604900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
    Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
    Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia.
    Shariat SF; Ashfaq R; Roehrborn CG; Slawin KM; Lotan Y
    J Urol; 2005 Nov; 174(5):2046-50. PubMed ID: 16217391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between the prostatic tissue components and natural history of benign prostatic hyperplasia.
    Matsuda T; Fujime M; Suda K
    Anal Quant Cytol Histol; 2006 Jun; 28(3):121-4. PubMed ID: 16786720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.